Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
87 results about "Tissue transplant" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Edg receptor agonists
The present invention encompasses compounds of Formula 1: as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
Owner:MERCK SHARP & DOHME CORP
N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
The present invention encompasses compounds of Formula (I) as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
Owner:MERCK SHARP & DOHME CORP
Aminoalkylphosphonates and related compounds as Edg receptor agonists
Owner:MERCK & CO INC
Edg receptor agonists
Owner:MERCK SHARP & DOHME CORP
3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
The present invention encompasses compounds of Formula I: (I) as well as the pharmaceutically acceptable salts thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
Owner:MERCK & CO INC
Methods and active substances for protecting organs
InactiveUS6924267B2Avoid problemsAvoid dysfunctionPeptide/protein ingredientsAntinoxious agentsMedicineTissue transplant
The present invention comprises a method of protecting organs or tissue susceptible to reperfusion-induced dysfunction after ischemia. The method comprises parenterally administering to a patient a therapeutical composition containing natural alpha-1 acid glycoprotein, natural alpha-1 antitrypsin or a mixture thereof. Alternatively, organ or tissue transplants can be contacted with natural alpha-1 acid glycoprotein, natural alpha-antitrypsin or mixtures by perfusing or flushing them with a solution containing natural alpha-1 acid glycoprotein, natural alpha-1 antitrypsin or mixtures thereof in a concentration of 0.1 to 5 g / l.
Owner:SUOMEN PUNAINEN RISTI VERIPALVELU
1-(Amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists
The present invention encompasses compounds of Formula (I): as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
Owner:MERCK SHARP & DOHME CORP
Surrogate tolerogenesis for the development of tolerance to xenografts
InactiveUS6060049AIncrease differentiationIncreased proliferationBiocideGenetic material ingredientsHematopoietic cellTolerability
PCT No. PCT / US94 / 05844 Sec. 371 Date Jun. 6, 1995 Sec. 102(e) Date Jun. 6, 1995 PCT Filed May 24, 1994 PCT Pub. No. WO94 / 27622 PCT Pub. Date Dec. 8, 1993This invention provides a method for developing immune tolerance in xenogeneic organ graft recipients, in which lympho-hematopoietic cells from an intended organ graft recipient are differentiated within a xenogeneic surrogate, such as a fetal animal. After birth of the surrogate, the matured lympho-hematopoietic cells containing antigen specific regulatory cells, including suppressor cells, veto cells, select B cells, anti-idiotype antibodies, and other related factors responsible for antigen specific tolerance in a surrogate animal are reintroduced into the intended organ graft recipient, in conjunction with an organ transplant or a tissue transplant from the xenograft surrogate. The invention also provides an organ graft repopulated with cells from the intended organ graft recipient produced in a surrogate animal.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists
The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
Owner:MERCK & CO INC
Cell population with enhanced transplantation activity
InactiveUS20100303766A1Excellent migration ability and engraftment abilityRestore damageBiocideNervous system cellsDamages tissueHematopoietic stem cell transplantation
A cell having excellent migration ability and engraftment ability to tissues is required for the restoration and the like of damaged tissues making use of a hematopoietic stem cell transplantation or a stem cell transplantation. By the present invention, a cell population having excellent migration ability and engraftment ability to tissues, a pharmaceutical preparation comprising said cell and a transplantation method of said cell are provided. The cell of the present invention is useful for hematopoietic stem cell transplantation and restoration of damaged tissues using stem cell transplantation and the like.
Owner:KYOWA HAKKO KIRIN CO LTD
Chimeric Avian-Based Screening System Containing Mammalian Grafts
ActiveUS20090064349A1The process is convenient and fastConvenient and efficient systemCompound screeningVirusesMammalModel system
The present invention relates to animal model systems comprising a chimera between an avian embryo and a mammalian organism. Specifically, chimeric model systems comprising normal, diseased or genetically transformed mammalian cells and tissues transplanted into avian embryos, and uses thereof for in vivo testing of drugs and therapeutic modalities are disclosed.
Owner:BAR ILAN UNIV +1
3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists
The present invention encompasses compounds of Formula I: (I) as well as the pharmaceutically acceptable salts thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
Owner:MERCK & CO INC
1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists
The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
Owner:MERCK & CO INC
Aminoalkylphosphonates and related compounds as edg receptor agonists
The present invention encompasses compounds of formula (II); as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
Owner:DOHERTY GEORGE A +1
Methods and active substances for protecting organs
InactiveUS20050277106A1Avoid dysfunctionPreventing transplantPeptide/protein ingredientsDead animal preservationMedicineTissue transplant
The present invention comprises a method of protecting organs or tissue susceptible to reperfusion-induced dysfunction after ischemia. The method comprises parenterally administering to a patient a therapeutical composition containing natural alpha-1 acid glycoprotein, natural alpha-1 antitrypsin or a mixture thereof. Alternatively, organ or tissue transplants can be contacted with natural alpha-1 acid glycoprotein, natural alpha-1 antitrypsin or mixtures by perfusing or flushing them with a solution containing natural alpha-1 acid glycoprotein, natural alpha-1 antitrypsin or mixtures thereof in a concentration of 0.1 to 5 g / l.
Owner:SUOMEN PUNAINEN RISTI VERIPALVELU
1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as Edg receptor agonists
The present invention encompasses compounds of Formula (I): as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
Owner:MERCK SHARP & DOHME CORP
Tissue engineered bone-cartilage complex tissue graft and preparation method thereof
The invention provides a tissue engineered bone-cartilage composite tissue transplant and a preparation method thereof, and belongs to the tissue engineering field. The method comprises the following steps: seed cells are implanted on a scaffold material and cultured in vitro to form the tissue engineered bone-cartilage composite tissue transplant; the seed cells are osteogenic stem cells; the scaffold material comprises an osteogenic part and a chondroblast part, and the osteogenic part is added with an osteoblast induction factor and modified by a type-I collagen in a preparation process; and the chondroblast part is added with a chondroblast induction factor and modified by a type-II collagen. Bone marrow mesenchymal stem cells are successfully induced into osteocytes and chondrocytes, and bone tissues and cartilage tissues are formed after the obtained transplant is transplanted in vivo. Satisfactory effect is obtained from the tissue engineered bone-cartilage composite tissue which is constructed by the transplant.
Owner:JINAN UNIVERSITY
3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
The present invention encompasses compounds of Formula (I): as well as the pharmaceutically acceptable salts thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
Owner:MERCK & CO INC
Aminoalkylphosphonates and related compounds as edg receptor agonists
The present invention encompasses compounds or Formula (I): as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
Owner:MERCK & CO INC
Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
Compositions and methods for inhibiting CD40-directed activities that are mediated via the binding of C4BP to CD40 are provided. The compositions of the invention include anti-CD40 antibodies, or antigen-binding fragments thereof, that have the following characteristics: 1) are free of significant CD40 agonist activity when bound to CD40 antigen; and 2) are capable of specifically binding to CD40 antigen expressed on the surface of cells, wherein this binding to CD40 antigen blocks C4BP-mediated CD40 signaling, thereby inhibiting one or more CD40-directed activities. These antagonist anti-CD40 antibodies can effectively be used to treat CD40-associated diseases that are mediated by C4BP stimulation of CD40 signaling, including cancers, such as B cell-related cancers and solid tumors, and diseases or disorders that have an autoimmune and / or inflammatory component, including organ and tissue transplant rejection.
Owner:NOVARTIS VACCINES & DIAGNOSTICS INC
Composite for Thermo-Sensitive Cell-Tissue Transplanted Scaffold and Use thereof
A composite comprising a stem cell; a biodegradable layer, which can provide an environment for the stem cell to grow and to differentiate, and; a N-isopropylacrylamide (NIPAAm), which can polymerize with the biodegradable layer and possess the temperature-responsive character for easy stripping. This invention also provides a method of treating a subject with a skin defect by covering the composite of the present invention on the skin defect of the subject in need of such treatment. Furthermore, using this composite with different growth factors, stem cells can be induced to differentiate into skin-related, neuronal cells, neuron, and insulin-positive cells in biodegradable scaffolds as well as transplanted graft. Finally, this invention also provides a quick and convenient method of monitoring cell growth or tissue engineering in an animal.
Owner:VETERANS GEN HOSPITAL TAIPEI
3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
Owner:MERCK & CO INC
Methods of expanding ex vivo natural killer t (NKT) cells and therapeutic uses thereof
InactiveUS20170029777A1Strong cytotoxicityCulture processMammal material medical ingredientsAutoimmune responsesTissue transplant
The present invention is directed to novel methods of producing ex vivo natural killer T (NKT) cells, and therapeutic uses thereof for treatment of certain conditions including cancer, autoimmunity, inflammatory disorders, allergic disorders, tissue transplant-related disorders, and infections.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC
Amine compound for inhibiting SSAO/VAP-1 and use thereof
An amine compound serving as a semicarbazide-sensitive amine oxidase (SSAO) and / or vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, and an application thereof in medicines that can be used for treating inflammation and / or inflammation related diseases, diabetes and / or a disease related diabetes, psychiatric disorder, ischemic disease, vascular disease, fibrosis, or tissue transplant rejection.
Owner:SUNSHINE LAKE PHARM CO LTD
Cultured tissue transplant device
ActiveUS20120191184A1Precise positioningExact matchEye implantsSurgeryTissue transplantBiomedical engineering
A device for transplanting a graft such as a layer or layers of cultivated, autologous, allogenic or xenogenic cells to cover an accidental or surgical wound. The graft is cultivated and carried on a bed of collagen or other dissolvable or releasable material mounted on a protective substrate molded to conform to the profile of the wounded area and provided with a lateral attachment zone. The device facilitates the graft cultured in vitro to the recipient surface.
Owner:CHEN PAUL HONG DZE
Immunosuppressive drug combination for a stable and long term engraftment
InactiveUS20130183322A1Reduced graft rejectionReduce rejectionOrganic active ingredientsPeptide/protein ingredientsImmunosuppressive drugS1P Receptor
A method of treating a subject in need of a cell or tissue transplant is disclosed. The method comprising (a) transplanting a non-syngeneic cell or tissue transplant into the subject, wherein the transplant comprises bone marrow or lymphoid cells; and (b) administering to the subject a therapeutically effective amount of an immunosuppressive regimen comprising a Sphingosine 1-Phosphate Receptor Agonist, a B7 molecule inhibitor and a CD2 / CD58 pathway inhibitor, thereby treating the subject.
Owner:YEDA RES & DEV CO LTD
Method for inhibiting transplant rejection
A method for inhibiting rejection of tissues transplanted into a mammalian host is disclosed. Treatment of the tissues with an enzyme or combination of enzyme, particularly papain, to eliminate cell surface structures necessary for recognition by the host's immune system, particularly MHC Class I molecules, avoids or reduces the attack of the host's immune system on the transplanted tissues. Tissues that are enzymatically shaved of MHC Class I antigens and / or other critical adhesion molecules can be rendered at least temporarily resistant or immune to attack by cytolytic T lymphocytes, helper T lymphocytes, antibodies, or other effector cells of a host's immune system, thereby enhancing the survivability of the tissues in the host after transplant.
Owner:FAUSTMAN DENISE L
Protein biomarkers and therapeutic targets for autoimmune and alloimmune diseaes
ActiveUS20120077209A1Solid foundationMicrobiological testing/measurementDisease diagnosisAutoimmune diseaseTissue transplant
A method for characterizing the risk a subject will develop an autoimmune and / or alloimmune disease following tissue transplant includes obtaining a biological sample from the subject, wherein the subject has received the tissue transplant determining in the biological sample a level of at least one protein selected from Tables 1-4, comparing the measured level of the at least one protein to a control value, and characterizing a subject as at greater risk of developing an autoimmune disease and / or alloimmune disease if the level of at least one protein determined is increased or decreased compared to the control value.
Owner:CASE WESTERN RESERVE UNIV
Long-acting broad-spectrum chemotactic factor receptor inhibiting matter
A chimeric protein compound for durable and efficient suppression to different chemotactic factor receptors, its nucleic acid sequence, and the process for preparing and testing its products are disclosed. It can be used to prevent and cure HIV infection, tumor transfer, tissue transplant rejection and self immunopathy. Its advantages are high durability, broad spectrum, and high selectivity.
Owner:龚小迪
NF-kB inhibitors and uses threreof
A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma, etc.), antibacterial agents, and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-kappaB as well as potent activity against the Gram (+) bacterium. The compositions are also useful for treating autoimmune diseases and for inhibiting rejection of organ and tissue transplants.
Owner:BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com